THERAVANCE BIOPHARMA, INC. (TBPH) Files An 8-K Other Events

Item8.01 Other Events

As previously disclosed on the Current Report on Form8-K filed on
November2, 2016, Theravance Biopharma,Inc. (the Company) entered
into an underwriting agreement dated October27, 2016 (the Equity
Underwriting Agreement) with Leerink Partners LLC and Evercore
Group L.L.C., as representatives of the underwriters named
therein (the Equity Underwriters), in connection with the offer
and sale by the Company of 3,850,000 ordinary shares of the
Company, par value $0.00001 per share (Ordinary Shares). to the
terms of the Equity Underwriting Agreement, the Company granted
the Equity Underwriters an option (the Option) to purchase up to
an additional 577,500 Ordinary Shares (the Option Shares). The
Equity Underwriters exercised the Option in full and the sale of
the Option Shares by the Company closed on November14, 2016.

Attached as Exhibit5.1 to this Current Report on Form8-K is a
copy of the opinion of Maples and Calder relating to the Option
Shares.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About THERAVANCE BIOPHARMA, INC. (TBPH)